News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Dowpharma Announces Multi-Product License Agreement with Merck & Co., Inc.
February 26, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MIDLAND, MICH - February 22, 2007 -- Dowpharma today announced that Merck & Co., Inc. has entered into a multi-product commercial license agreement for Pfenex Expression Technology™, a Pseudomonas-based technology from Dowpharma.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
Manufacturing
Violations at Novo’s Indiana Plant ‘Unacceptable,’ FDA Says
October 14, 2025
·
2 min read
·
Tristan Manalac
Artificial intelligence
Takeda Makes $1B+ AI Bet With Nabla to Build Out Early Pipeline
October 14, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Novo Retreats From Cell Therapy, Axes Hundreds as Restructuring Rolls On
October 13, 2025
·
2 min read
·
Tristan Manalac
IN PARTNERSHIP WITH EVOTEC
Strategic Drug Development in a Funding Crisis: Expert Insights on Risk Profiling, Efficiency, and Innovation
October 13, 2025
·
8 min read
·
BioSpace Insights
